Source: ALL
Disease Score gda Association Type Type Original DB Sentence supporting the association PMID PMID Year
CUI: C0026850
Disease: Muscular Dystrophy
Muscular Dystrophy
0.010 Biomarker disease BEFREE These results suggest that GYLTL1B may be a candidate gene for muscular dystrophy and that its overexpression could compensate for the deficiency of both LARGE and other glycosyltransferases. 15661757 2005
CUI: C0027051
Disease: Myocardial Infarction
Myocardial Infarction
0.100 GeneticVariation disease GWASDB Association of a polymorphism of BTN2A1 with myocardial infarction in East Asian populations. 21211798 2011
CUI: C0006826
Disease: Malignant Neoplasms
Malignant Neoplasms
0.020 AlteredExpression group BEFREE Finally, our analysis of LARGE2 expression in human cancer specimens reveals that LARGE2 is significantly down-regulated in the context of prostate cancer, and that its reduction correlates with disease progression. 23223448 2013
CUI: C0376358
Disease: Malignant neoplasm of prostate
Malignant neoplasm of prostate
0.020 AlteredExpression disease BEFREE Finally, our analysis of LARGE2 expression in human cancer specimens reveals that LARGE2 is significantly down-regulated in the context of prostate cancer, and that its reduction correlates with disease progression. 23223448 2013
CUI: C0600139
Disease: Prostate carcinoma
Prostate carcinoma
0.020 AlteredExpression disease BEFREE Finally, our analysis of LARGE2 expression in human cancer specimens reveals that LARGE2 is significantly down-regulated in the context of prostate cancer, and that its reduction correlates with disease progression. 23223448 2013
CUI: C1306459
Disease: Primary malignant neoplasm
Primary malignant neoplasm
0.020 AlteredExpression group BEFREE Finally, our analysis of LARGE2 expression in human cancer specimens reveals that LARGE2 is significantly down-regulated in the context of prostate cancer, and that its reduction correlates with disease progression. 23223448 2013
CUI: C0006826
Disease: Malignant Neoplasms
Malignant Neoplasms
0.020 AlteredExpression group BEFREE Furthermore, analysis of gene expression profiles of clinical samples in The Cancer Genome Atlas reveals negative correlation of LARGE2 and ZEB1 expression in various cancers. 25455932 2015
CUI: C0376358
Disease: Malignant neoplasm of prostate
Malignant neoplasm of prostate
0.020 AlteredExpression disease BEFREE In the case of prostate cancer, one mechanism that contributes to αDG hypoglycosylation is transcriptional down-regulation of LARGE2 (GYLTY1B), a glycosyltransferase that produces the functional (laminin-binding) glycan on αDG, but the mechanism(s) underlying reduction of LARGE2 mRNA remain unclear. 25455932 2015
CUI: C0600139
Disease: Prostate carcinoma
Prostate carcinoma
0.020 AlteredExpression disease BEFREE In the case of prostate cancer, one mechanism that contributes to αDG hypoglycosylation is transcriptional down-regulation of LARGE2 (GYLTY1B), a glycosyltransferase that produces the functional (laminin-binding) glycan on αDG, but the mechanism(s) underlying reduction of LARGE2 mRNA remain unclear. 25455932 2015
CUI: C1306459
Disease: Primary malignant neoplasm
Primary malignant neoplasm
0.020 AlteredExpression group BEFREE Furthermore, analysis of gene expression profiles of clinical samples in The Cancer Genome Atlas reveals negative correlation of LARGE2 and ZEB1 expression in various cancers. 25455932 2015
CUI: C0027627
Disease: Neoplasm Metastasis
Neoplasm Metastasis
0.010 Biomarker phenotype BEFREE Collectively, our results suggest that LARGE2 is negatively regulated by Snail and/or ZEB1, revealing a mechanistic basis for αDG hypoglycosylation during prostate cancer progression and metastasis. 25455932 2015
Conventional (Clear Cell) Renal Cell Carcinoma
0.010 AlteredExpression disease BEFREE Reduced levels of GYLTL1B and ISPD mRNA associated with increased patient mortality and are the likely cause of αDG hypoglycosylation in ccRCC. 26220087 2015
CUI: C1285498
Disease: Vegetation
Vegetation
0.010 GeneticVariation disease BEFREE The objectives were to: 1) assess the macroaggregate distribution (proportional mass, class mass) and the SOC and particulate organic carbon (POC) stocks of extra-large (8-19mm), large (2-8mm) and small (0.25-2mm) macroaggregate size classes managed for two decades by NT, and 2) assess the recovery of SOC stocks in extra-large macroaggregates compared to adjacent native vegetation (Andropogon sp., Aristida sp., Paspalum sp., and Panicum sp.). 29122351 2018
CUI: C0007138
Disease: Carcinoma, Transitional Cell
Carcinoma, Transitional Cell
0.010 Biomarker disease BEFREE Ureteroscopic Management of Large ≥2 cm Upper Tract Urothelial Carcinoma: A Comprehensive 23-Year Experience. 29964129 2018
CUI: C2145472
Disease: Urothelial Carcinoma
Urothelial Carcinoma
0.010 Biomarker disease BEFREE Ureteroscopic Management of Large ≥2 cm Upper Tract Urothelial Carcinoma: A Comprehensive 23-Year Experience. 29964129 2018
CUI: C0005890
Disease: Body Height
Body Height
0.100 GeneticVariation phenotype GWASCAT Leveraging Polygenic Functional Enrichment to Improve GWAS Power. 30595370 2019
CUI: C0263912
Disease: Rotator cuff syndrome
Rotator cuff syndrome
0.010 Biomarker disease BEFREE Twenty-three patients undergoing repair of full-thickness large (2-tendon) or massive (3-tendon) rotator cuff tears augmented with a bioinductive collagen patch were enrolled in a prospective single-arm proof-of-principle study. 31150274 2019